TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CoQ10 and D-ribose in Patients With Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with HFpEF within a 6-month period~* New York Heart Association (NYHA) Classification II-III HF~* Have left ventricular ejection fraction (EF) ≥ 50% documented by an echocardiogram~* Have a telephone or reliable phone contact~* Have their own means of transportation to the study site~Exclusion Criteria:~* Acute coronary syndrome in the past 12 weeks~* Significant valvular heart disease~* Severe cardiac fibrosis (galectin-3 level \> 26 ng/ml)~* Constrictive pericardium~* Pulmonary fibrosis~* Congenital heart disease~* Hypertrophic or infiltrative cardiomyopathy~* Heart transplant~* Left ventricular assist device~* Heart failure (HF) associated hospital admission or emergency room visit within past 30 days~* Recent percutaneous coronary intervention~* Significant renal and/or hepatic dysfunction~* Severe cognitive impairment~* Consumption of any CoQ10 (ubiquinol) or D-ribose supplements

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo Only (Type: PLACEBO_COMPARATOR): Participants in this group will receive placebo pills and placebo powder.
- CoQ10 Only (Type: ACTIVE_COMPARATOR): Participants in this group will receive CoQ10 pills and placebo powder
- D-ribose Only (Type: ACTIVE_COMPARATOR): Participants in this group will receive placebo pills and D-ribose oral powder.
- CoQ10 + D-ribose (Type: EXPERIMENTAL): Participants in this group will receive CoQ10 pills and D-ribose oral powder.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Vulvovaginal candidiasis infection is diagnosed, the symptoms evaluated using a numerical rating system based on severity (absent=0; mild=1; moderate=2; severe=3) with a minimum VVC Composite Signs/Symptoms score of 7~* Subject completes the informed consent process~* Subject agrees to take study medication when scheduled~* Subject complies with all clinical trial instructions. Commits to all follow-up visits~* Subject agrees to abstain from sexual intercourse from the time of randomization through the first seven days immediately following treatment~Exclusion Criteria:~* had any other sexually transmitted disease or gynaecological abnormality requiring treatment~* had a disease known to predispose to candidiasis such as diabetes mellitus, or were receiving antibiotics or corticosteriods~* had used antifungal medication in the week before entry; or~* were expected to menstruate within seven days of the start of treatment~* infected more than one candida species

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- Terconazole Vaginal Suppository (Type: EXPERIMENTAL): Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
- Fluconazole (Type: ACTIVE_COMPARATOR): orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Auditory Processing in Spanish-English Bilinguals: Is Performance Better When Tested in Spanish or English?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bilingual Spanish-English speakers~* Must have learned Spanish first followed by English~* Proficiency in both languages~* Normal hearing~Exclusion Criteria:~* Hearing loss~* History of traumatic brain injuries (TBI)~* Neurological issues~* Auditory processing concerns

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- L1 First (Type: EXPERIMENTAL): All participants will receive both experimental conditions (i.e., test materials in English, test materials in Spanish) in a counterbalanced order. Individuals in this arm receive Spanish materials first, then English test materials.
- L2 First (Type: EXPERIMENTAL): All participants will receive both experimental conditions (i.e., test materials in English, test materials in Spanish) in a counterbalanced order. Individuals in this arm receive English materials first, then Spanish test materials.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness of Telemedicine in Primary Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients that are attributed to primary care clinics across four health systems in the INSIGHT (Mount Sinai Health System and Weill Cornell Medicine), OneFlorida (University of Florida Health), and STAR (University of North Carolina Health) CRNs.~* Patients received two or more outpatient visits at a participating practice during a one-year period before the COVID-19 pandemic,~* Patients had one or more of five chronic illnesses (asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), diabetes, hypertension) as defined by the Medicare Chronic Conditions Warehouse algorithm~Exclusion Criteria:~* Patients who tested COVID-positive~* Patients from hospice and palliative care practices~* Patients from osteopathic medicine practices~* Patients from pediatric practices~* Patients that did not reside in states where the four health systems were located: the New York-Tri State Area (Connecticut, New York, and New Jersey), Florida, and North Carolina.~* Patients that moved out of state (or out of the New York-Tri State Area) or who died during the study period were also excluded.~* Patients who were not continuously enrolled over the entire study period (2019-2021).

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- High Telemedicine (Type: None): Patients in practices that had high telemedicine use, based on the percent of visits the practice delivered via telemedicine from April 2020 to December 2021 (the study post-period)
- Low Telemedicine (Type: None): Patients in practices that had some telemedicine use, based on the percent of visits the practice delivered via telemedicine from April 2020 to December 2021 (the study post-period)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BVAIT: B-Vitamin Atherosclerosis Intervention Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female (postmenopausal)~* 40 years or older~* Fasting plasma homocysteine 8.5 micromoles per liter (µmol/L) or greater~Exclusion Criteria:~* Any clinical signs or symptoms of cardiovascular disease (CVD)~* Diabetes mellitus or fasting serum glucose 140 mg/dL or greater~* Triglyceride (TG) levels 500mg/dL or greater~* Serum creatinine greater than 1.6 mg/dL~* Uncontrolled hypertension (systolic blood pressure 160 mmHg or greater and/or diastolic blood pressure 100 mmHg or greater)~* Thyroid disease (untreated)~* Life threatening disease with prognosis less than 5 years~* Alcohol intake greater than 5 drinks per day (1 drink = 1 1/2 oz distilled spirits, 4 oz wine, or 12 oz beer) or substance abuse (intravenous drug use, cocaine use)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 or type 2 diabetes mellitus at screening~* Painful distal symmetric polyneuropathy~* At screening, a pain scale of ≥ 40 mm~Exclusion Criteria:~* HbA1c (National Glycohemoglobin Standardization Program) \> 10.0%

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): placebo group (14 weeks)
- DS-5565 15mg (Type: EXPERIMENTAL): DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
- DS-5565 20 mg group (Type: EXPERIMENTAL): DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
- DS-5565 30 mg group (Type: EXPERIMENTAL): DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. \> Age of 18 at time of first visit.~2. HIV uninfected~3. Willing and able to provide written informed consent.~4. Willing and able to provide adequate locator information.~5. Willing and able to return to all study visits.~6. Willing to participate in all study procedures.~7. Childbearing age: Willing to use contraception for as long as they are on study medication plus 7 days after. (Appendix A: list of approved contraception).~8. Possible sexual exposure to HIV-1, recent enough to permit receiving the first dose of study medication within 72 hours from the end of the exposure. A possible exposure could include:~   1. Condomless anal, vaginal, oral, or mucosal (e.g. conjunctival) exposure to ejaculate from a partner who is HIV-1 infected or high risk for HIV infection and of unknown HIV-1 serostatus (may include protected sexual exposure with condom failure, breakage or slippage); or~  2. Condomless penile exposure to cervicovaginal secretions or anorectal secretions from a partner who is HIV-1 infected or high risk for HIV infection and of unknown HIV-1 serostatus (may include protected sexual exposure with condom failure, breakage or slippage)~Exclusion Criteria:~1. An active psychiatric illness or active drug or alcohol abuse that, in the opinion of the investigator, could prevent compliance with study procedures.~2. Pregnancy and/or breastfeeding.~3. People who are actively trying to become pregnant.~4. Acute or chronic hepatitis B infection.~5. Acute or chronic renal disease.~6. Creatinine clearance at or below 30 mL/min (Cockcroft-Gault0 Known intolerance or allergy to tenofovir disoproxil fumarate, tenofovir alafenamide, emtricitabine, or bictegravir.~8. Currently taking or plans to take prohibited medication while enrolled in the study. (Appendix B: complete list of prohibited medications).~9. Non-English speakers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Open Label Biktarvy (Type: EXPERIMENTAL): Single arm all participants receive open label study product intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Definitive diagnosis of alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.~* At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.~* Clinical lab results within the normal range~Exclusion Criteria:~* Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis on the scalp.~* Treatment with systemic immunosuppressive medications or biologics.~* Vaccination with herpes zoster vaccine or any live virus within 6 weeks of screening or during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: CTP-543 4 mg BID (Type: EXPERIMENTAL): Participants will receive CTP-543 4 mg tablets, twice daily for up to 24 weeks.
- Cohort 2: CTP-543 8 mg BID (Type: EXPERIMENTAL): Participants will receive CTP-543 8 mg tablets, twice daily for up to 24 weeks.
- Cohort 3: CTP-543 12 mg BID (Type: EXPERIMENTAL): Participants will receive CTP-543 12 mg tablets, twice daily for up to 24 weeks.
- Combined Placebo (Type: PLACEBO_COMPARATOR): Participants will receive CTP-543 matched placebo tablets, twice daily for up to 24 weeks in Cohorts 1, 2, and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-negative by rapid test, or documentation of HIV infection with a laboratory result of a positive HIV test;~2. male gender;~3. reports having anal sex with men in the prior 3 months while using methamphetamine;~4. diagnosed with methamphetamine dependence as determined by SCID;~5. interested in stopping or reducing methamphetamine use;~6. at least one methamphetamine-positive urine at screening and run-in period;~7. no known allergies to mirtazapine;~8. no current acute illnesses requiring prolonged medical care;~9. no chronic illnesses that are likely to progress clinically during trial participation;~10. able and willing to provide informed consent and to be followed over a 3-month period;~11. age 18-60 years;~12. baseline CBC, total protein, albumin, glucose, alk phos, creatinine, BUN and electrolytes without clinically significant abnormalities as determined by investigator in conjunction with symptoms, physical exam, and medical history.~Exclusion Criteria:~1. evidence of current major depression, as determined by SCID;70~2. history of bipolar disorder or psychosis, as determined by SCID;~3. taking anti-depressant or other psychotropic medication within the last 30 days, including mirtazapine or a monoamine oxidase (MAO) inhibitor;~4. currently using or unwilling not to use pseudoephedrine-containing products for trial duration (causes false positive urines for methamphetamine use);~5. current CD4 count \< 200 cells/mm3;~6. measured moderate or severe liver disease (AST, ALT, and total bilirubin \> 3 times upper limit of normal) and/or any symptoms of current liver disease;~7. impaired renal function (creatinine clearance \< 60 ml/min);~8. currently participating in another research study;~9. any condition that, in the principal investigator's judgment, interferes with safe study participation or adherence to study procedures.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Mirtazapine (Type: ACTIVE_COMPARATOR): mirtazapine 30 mg daily
- Placebo (Type: PLACEBO_COMPARATOR): placebo 30 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female: 50 years of age or older~* \>5 years since last menses natural or surgical~* have lumbar spine or total hip BMD more that 2.5 SD below the young adult mean, or have lumbar spine or total hip BMD more than 2.0 SD below the young adult female mean value and also have at least one prevalent vertebral body fracture~Exclusion Criteria:~* history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia~* BMI \>32 kg/m~* use of medications within 3 months of starting study drug that impact bone metabolism such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and parathyroid hormone~* hypocalcemia or hypercalcemia of any cause~* markedly abnormal clinical laboratory measurements that are assessed as clinically significant by the investigator

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Before Breakfast (Type: ACTIVE_COMPARATOR): 5 mg / Immediate-release Risedronate (At Least 30 Minutes Before Breakfast)
- 35 mg After Breakfast (Type: EXPERIMENTAL): 35 mg / Delayed-release Risedronate (Immediately Following Breakfast)
- 35 mg Before Breakfast (Type: EXPERIMENTAL): 35 mg / Delayed-release Risedronate (At Least 30 Minutes Before Breakfast)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients,~* Age between 35 -65 years,~* Diagnosed with UC established by colonoscopy and histology, and suffering from mild to moderate UC as defined by Modified Mayo Disease Activity Index (MMDAI) (score 3-9).~Exclusion Criteria:~* Patients with age \<35 years, \>65 years,~* Pregnancy, planned pregnancy, breastfeeding women,~* Evidence of severe disease (MMDAI \>10),~* Concurrent enteric infection,~* Use of antibiotics,~* Change in the dose of oral 5-aminosalicylic acid (5-ASA) within the past 4weeks, and use of rectal 5-ASA or steroids within 7 days before entry into the study,~* Received any investigational medicines within 3months,~* If they have significant hepatic, renal, endocrine, respiratory, neurological, or cardiovascular diseases

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Probiotic Formula Capsule (Type: EXPERIMENTAL): In this intervention arm, the patients will receive oral viable capsules of probiotic contain (1\*10 10 colony-forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
- Placebos (Type: PLACEBO_COMPARATOR): In this intervention arm Placebo arm received three oral viable capsules daily, containing polysaccharides, without any viable probiotics matching the probiotic capsules in appearance, smell, and taste.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endotracheal Intubation Using Videolaryngoscopy Versus Conventional Direct Laryngoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective or emergent surgery requiring oral endotracheal intubation for general anesthesia.~Exclusion Criteria:~* The attending anesthesiologist prefers a specific approach for a particular patient~* Awake fiberoptic intubation is clinically indicated~* Insertion of double-lumen tube.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- videolaryngoscopy (Type: EXPERIMENTAL): Initial intubation performed using GlideScope videolaryngoscope.
- conventional direct laryngoscopy (Type: ACTIVE_COMPARATOR): Initial intubation performed using direct laryngoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete